

## **LOAN AGREEMENT**

between

**TONY G-CO INVESTMENT HOLDINGS LIMITED**

and

**ALCLIN MANUFACTURING PROPRIETARY LIMITED**

and

**ALCLIN PROPRIETARY LIMITED**

and

**CHRISTO GUSTAV COETZEE**

## CONTENT

Clause	Page No
1. Interpretation .....	3
2. Definitions .....	4
3. Incorporation of the Transaction Agreement.....	6
4. Conditions Precedent to this Agreement.....	6
5. Advance of Loan .....	7
6. Interest .....	9
7. Loan Denomination .....	9
8. Repayment of Loan .....	9
9. Alclin Manufacturing's Liability .....	11
10. Events of Default .....	11
11. Security .....	14
12. The Cession .....	14
13. Stipulatio Alteri .....	18
14. Specific Transaction Agreement Provisions.....	18
15. Counterparts.....	19

1. **Interpretation**

1.1 Any reference in this Agreement to:

- (a) a clause is, subject to any contrary indication, a reference to a clause of this Agreement;
- (b) a person is a reference to any natural or juristic person, firm, company, corporation, government, state, agency or organ of a state, association, trust or partnership (whether or not having separate legal personality);
- (c) any statute, regulation or other legislation is a reference to that statute, regulation or other legislation as amended or substituted from time to time;
- (d) a document or instrument includes the document or instrument as ceded, delegated, novated, altered, supplemented or replaced from time to time;
- (e) “including” or “in particular” does not limit the meaning of the preceding general words.

1.2 Headings are included in this Agreement for the purpose of convenience only and will not be used in its interpretation.

1.3 Unless the context indicates otherwise, in this Agreement a reference to the singular includes the plural and vice versa and a reference to any gender includes the other genders.

1.4 When any number of days is prescribed in this Agreement, the number excludes the first and includes the last day unless the last day falls on a day which is not a Business Day, in which case the last day will be the immediately preceding Business Day. Any reference to times of the day must be interpreted as references to local times in the relevant jurisdiction, unless the context indicates otherwise.

- 1.5 If a definition in this Agreement is substantive, conferring rights or imposing obligations, or both, on a Party, effect will be given to it as if it were a substantive term in the body of this Agreement.
- 1.6 The termination or expiration of this Agreement will not affect those terms in this Agreement which expressly provide that they will operate after termination or expiration or which of necessity must continue to have effect after termination or expiration, notwithstanding that the terms do not expressly provide this.
- 1.7 The terms of this Agreement have been negotiated by the Parties and drafted for the benefit of the Parties, and accordingly the rule of construction that a contract will be interpreted against or to the disadvantage of the party responsible for drafting the contract, will not apply.

## 2. **Definitions**

Unless expressly defined hereunder, terms with the first letter(s) capitalised shall, when used in this Agreement, bear the meanings assigned to them in the Transaction Agreement and shall be deemed to be incorporated herein and form part of this Agreement:

- 2.1 “Agreement” means this Loan Agreement including its annexures (if any);
- 2.2 “Auditors” means the Company’s auditors;
- 2.3 “Borrower” means Alclin;

2.4 “Borrower’s Nominated Account” means the following bank account:

Name of Accountholder	:	Alclin (Pty) Ltd
Bank	:	Nedbank Ltd
Branch	:	Still Bay, Western Cape
Branch Code	:	198765
Account Number	:	7579015560
Account Type	:	USD Foreign Currency Account
Swift Code	:	NEDSZAJJ
Reference	:	Tony G-Co

2.5 “Cession” means the cession recorded in clause 12;

2.6 “ESCO” means the manufacturer of the Machinery;

2.7 “Fifth and Further Loan Portions” means \$1 012 826. 08;

2.8 “First Loan Portion” means \$1 045 997.19;

2.9 “Fourth Loan Portion” means \$209 199.44;

2.10 “Interest Rate” means the Federal Funds Rate set by the Federal Open Market Committee of the Federal Reserve System of the United States of America, from time to time, which at the Signature Date is 5. 5% (five comma five percent); a letter or document setting out the Interest Rate and signed by any manager or assistant general manager of any branch of any commercial bank shall constitute *prima facie* proof of the Interest Rate;

2.11 “Lender” means the Subscriber;

2.12 “Obligors” means Alclin, Alclin Manufacturing, and “Obligor” means either one of them as the context requires;

2.13 “Outstanding Amount” means the aggregate amount from time to time outstanding under this Agreement, including any capital not paid, interest, fees and costs and all other amounts outstanding under this Agreement;

- 2.14 “Purpose” means the reason for the Borrower borrowing from the Lender, being the purchase of the Machinery and to fund working capital requirements, as detailed in clauses 5.1(b), 5.2(b), 5.3(b), 5.4(b) and 5.5(b);
- 2.15 “Quarter” means each consecutive three-month period, the first of which shall begin on 29 February 2024;
- 2.16 “Second Loan Portion” means \$129 367. 52;
- 2.17 “Security” means the security provided, or procured, by the Obligors to secure their indebtedness to the lender under the Agreement, including the Cession and the Notarial Bond;
- 2.18 “Signature Date” means the date of signature of this Agreement by the Party last signing;
- 2.19 “Third Loan Portion” means \$836 797. 75; and
- 2.20 “Transaction Agreement” means the transaction agreement concluded between the Parties, and which contemplates the conclusion of this Agreement.

### 3. **Incorporation of the Transaction Agreement**

- 3.1 This Agreement shall at all times be read together with and interpreted in the context of the Transaction Agreement.
- 3.2 Should there be any conflict with the provisions of this Agreement and the provisions of the Transaction Agreement, the provisions of this Agreement shall apply.
- 3.3 This is the “Loan Agreement” contemplated by the Transaction Agreement.

### 4. **Conditions Precedent to this Agreement**

- 4.1 This Agreement (except clauses 1 to 3, this clause 4 and clauses 10 to 15, all inclusive (**Surviving Clauses**)) is subject to the fulfilment, or waiver, of the conditions precedent (save for any condition which requires this Agreement to become unconditional) to the Transaction Agreement.

- 4.2 If the conditions precedent are not fulfilled, or where applicable, extended or waived, on or prior to the dates stipulated for such fulfilment, the provisions of this Agreement, except the Surviving Clauses, will never become effective.

5. **Advance of Loan**

5.1 First Loan Portion:

- (a) On the First Payment Date, provided the Further Payment Conditions are met, the Lender shall pay (or procure the payment of) \$1 617 093. 99 into the Borrower's Nominated Account, the First Loan Portion of which will be deemed to be:
  - (i) the Loan Portion of that payment; and
  - (ii) advanced to the Borrower under the terms of this Agreement.
- (b) The First Loan Portion must be used by the Borrower to pay ESCO.
- (c) Upon receipt of the First Loan Portion, the Borrower will procure that its Bankers immediately transfer the First Loan Portion to ESCO. The Borrower will send the relevant proof of payment to the Lender.

5.2 Second Loan Portion:

- (a) On the Second Payment Date, provided the Further Payment Conditions are met, the Lender shall pay (or procure the payment of) \$200 000. 00 into the Borrower's Nominated Account, the Second Loan Portion of which will be deemed to be:
  - (i) the Loan Portion of that payment; and
  - (ii) advanced to the Borrower under the terms of this Agreement.
- (b) The Second Loan Portion must be used by the Borrower for its working capital requirements.

5.3 Third Loan Portion:

- (a) On the Third Payment Date, provided the Further Payment Conditions are met, the Lender shall pay (or procure the payment of) \$1 293 675. 19 into the Borrower's Nominated Account, the Third Loan Portion of which will be deemed to be:
  - (i) the Loan Portion of that payment; and
  - (ii) advanced to the Borrower under the terms of this Agreement.
- (b) The Third Loan Portion must be used by the Borrower to pay ESCO.
- (c) Upon receipt of the First Loan Portion, the Borrower will procure that its Bankers immediately transfer the First Loan Portion to ESCO. The Borrower will send the relevant proof of payment to the Lender.

5.4 Fourth Loan Portion:

- (a) On the Fourth Payment Date, provided the Further Payment Conditions are met, the Lender shall pay (or procure the payment of) \$323 418. 80 into the Borrower's Nominated Account, the Fourth Loan Portion of which will be deemed to be:
  - (i) the Loan Portion of that payment; and
  - (ii) advanced to the Borrower under the terms of this Agreement.
- (b) The Fourth Loan Portion must be used by the Borrower to pay ESCO.
- (c) Upon receipt of the First Loan Portion, the Borrower will procure that its Bankers immediately transfer the First Loan Portion to ESCO. The Borrower will send the relevant proof of payment to the Lender.

5.5 Fifth and Further Loan Portions

- (a) On the Fifth and Further Payment Dates, provided the Further Payment Conditions are met, the Lender shall pay (or procure the payment of) \$1 565 812. 02 into the Borrower's Nominated Account, the Fifth and Further Portions of which will be deemed to be:



- (i) the Loan Portion of that payment/those payments; and
- (ii) advanced to the Borrower under the terms of this Agreement.

(b) The Fifth and Further Loan Portions must be used by the Borrower for its working capital requirements.

5.6 Any payments made (or procured) by the Lender prior to the First Payment Date shall be deemed to be consideration already paid for the relevant Subscription Shares – Alclin, Subscription Shares – Alclin Manufacturing and Loan Portion on the relevant date such payment was to be made.

6. **Interest**

The Loan will bear simple interest at the Interest Rate per annum, accruing daily on the outstanding principal balance of the Loan with effect from the date on which any tranche of the Loan is advanced and calculated on the basis of a 365-day year.

7. **Loan Denomination**

The Loan will be denominated in United States Dollars, and in this regard:

7.1 each advance of a Loan Portion will be denominated in United States Dollars; and

7.2 the repayments of the Loan plus any interest accrued thereof will be denominated in United States Dollars.

8. **Repayment of Loan**

8.1 Each Quarter:

- (a) all accrued interest; plus
- (b) an agreed component of the outstanding capital of the Loan,

shall be repaid by the Borrower, it being recorded that it shall be within the Lender's discretion to waive any portion of the interest.

- 8.2 The Borrower shall be entitled at any time to make additional payments to the Lender in reduction of or settlement of the outstanding balance of the Loan.
- 8.3 the Lender may, at its sole and absolute discretion, waive or postpone the payment of any portion of interest. Should the repayment of any portion of the interest be postponed by the Lender, that portion will be capitalised to the capital of the Loan.
- 8.4 Notwithstanding the above payment dates, the Borrower shall use its best endeavours, subject to available free cash flow and the Borrower's reasonably anticipated working capital requirements, to repay the full principal amount of the Loan together with accrued interest within 3 (three) years of the Closing Date.
- 8.5 All payments by the Borrower to the Lender in terms of this Agreement shall be paid as contemplated in this Agreement into the following bank account, or a bank account the Lender elects on written notice to the Borrower:

Name of Accountholder	:	Tony G-Co Investment Holdings Ltd
Bank	:	TD Canada Trust
Transit Number	:	02412
Instruction Number	:	004
Account Number	:	5266711
Reference	:	Alclin

- 8.6 Without in any way limiting or derogating from any other provision of this Agreement, the obligations to effect all payments to the Lender in accordance with this Agreement shall be absolute and unconditional, irrespective of any contingency whatsoever, including:
- (a) any right of set-off, counterclaim, recoupment, defence or other right;
  - (b) any insolvency, bankruptcy, administration, business rescue proceedings, reorganisation, arrangement, readjustment of debt, dissolution, liquidation or similar proceedings by or against Investec Bank or the Borrower;

- (c) any invalidity or unenforceability or lack of due authorisation of, or other defect in, this Agreement; and
- (d) any other cause which (but for the provisions of this clause 8.5) would or might have the effect of terminating, discharging or in any way affecting any obligation of the Obligors under this Agreement.

9. **Alclin Manufacturing's Liability**

- 9.1 Subject to clauses 9.2 and 9.3, Alclin Manufacturing hereby unconditionally and irrevocably guarantees in favour of the Lender, as principal obligation, the due and punctual payment and performance by Alclin of all and any obligations which Alclin may from time to time owe to the Lender, including under this Agreement.
- 9.2 To the extent that the guarantee recorded in clause 9.1 constitutes the provision of financial assistance by Alclin Manufacturing to Alclin, as contemplated in section 45 of the Companies Act, Alclin Manufacturing's liability hereunder shall be limited to an amount such that immediately after its provision it would satisfy the solvency and liquidity test as contemplated in the Companies Act.
- 9.3 For the avoidance of doubt, under no circumstances will Alclin Manufacturing's liability be an amount that would render it guaranteeing Alclin's obligations in breach of the Companies Act.

10. **Events of Default**

- 10.1 An Event of Default shall occur if:
  - (a) either of the Obligors or Coetzee breaches any of their obligations in terms of this Agreement and fail to remedy such breach (if capable of remedy) within 10 (ten) Business Days of receipt of written notice from the Lender requiring remedy thereof; or
  - (b) either of the Obligors and/or Coetzee commits an act of insolvency as defined in the Insolvency Act, 1936 (as amended); or

- (c) either of the Obligors is unable or ceases for any reason, whatsoever, to conduct its normal line of business in an ordinary regular course; or
- (d) either of the Obligors and/or Coetzee compromise or attempt to compromise generally with its creditors; or
- (e) any asset of any of the Obligors is attached under warrant of execution and it fails, within 10 (ten) days of such attachment to take necessary steps to have such attachment set aside and thereafter, pursue such steps with due diligence; or
- (f) an order of court (whether provisional or final), unless pursuant to a re-organisation, reconstruction or amalgamation consented to by the Lender, is granted for the winding up of either of the Alclin Companies or the members of either of the Alclin Companies effectively resolve, otherwise than pursuant to the re-organisation, reconstruction or amalgamation consented to by the Lender, to voluntarily wind up either of the Alclin Companies; or
- (g) a business rescue practitioner is appointed in respect of either of the Alclin Companies or in respect of all or any material part of its assets; or
- (h) the use by the Borrower of the Loan for purposes other than Purpose; or
- (i) the Alclin Companies and/or Coetzee breach the Transaction Agreement;
- (j) the Alclin Companies and/or Coetzee breach the Subscription Agreement or any demand is made by the Lender for any repayment of funds advanced by the Lender in terms of the Subscription Agreement;
- (k) the Alclin Companies and/or Coetzee breach the Shareholder Agreements;

- (l) any warranty, representation or statement made by any of the Alclin Companies and/or or Coetzee in connection with the Transaction Agreement or this Agreement is breached or is untrue or incorrect in any material respect or if any of the Alclin Companies and/or or Coetzee has failed to disclose any fact or defect which, in the opinion of the Lender, is material to this Agreement; or
- (m) the GMP certification is not achieved by 31 May 2024, to the satisfaction of the Lender; or
- (n) the costs in respect of the Clinical Trials materially exceed \$1 000 000. 00; or
- (o) in the reasonable opinion of the Lender, a third party, in any Territory within the world, concludes any Clinical Trials and/or registrations materially similar to the DMF; or
- (p) in the reasonable opinion of the Lender, Alclin does not adequately initiate, develop and expand its strategy for distribution through e-commerce channels using both its own on-line platform as well as third party partnerships.

10.2 Upon, or at any time after, the occurrence of an Event of Default in relation to any of the Obligors, the Lender:

- (a) may declare all or any part of the Outstanding Amount to be immediately repayable (whereupon the same shall become so payable together with accrued interest thereon and any other sums, then owed by the Borrower hereunder);
- (b) will have no obligation to advance any further amounts to the Borrower; and
- (c) may cancel this Agreement without prejudice to such other rights as the Lender may have at law.

11. **Security**

11.1 As security for the obligations of the Borrower to the Lender arising from, amongst other things, the terms of this Agreement:

- (a) the Obligors shall do all things to procure and maintain the registration of the Notarial Bond; and
- (b) provide the Cession.

11.2 The Lender has the right at any time, subject to the provision of *inter alia* section 45 of the Companies Act, to require the Obligors to (and the Obligors will as soon as possible, and in any event within 7 (Seven) Business Days) provide additional security on such terms and conditions as the Lender requires if, in the Lender's reasonable discretion, the value of any Security provided in terms of any Transaction Document has diminished. Should a dispute arise as to the value by which the Security has diminished, the Lender has the right promptly to refer the dispute to an architect or a valuer, of not less than 10 (Ten) years' standing practising in the region in which the Borrower operates (if the dispute relates to a property valuation), or to a director of an audit or legal firm (if the dispute relates to any other Security), whose decision will (save in the event of manifest error) be final and binding on the Parties.

11.3 The Lender may in its sole discretion, from time to time, revalue the Security.

11.4 The Alclin Companies consent to any Tony G-Co Nominee ceding any claims it has against the Alclin Companies to the Lender in order for those claims to be secured by the Notarial Bond.

12. **The Cession**

12.1 For the purposes hereof:

- (a) "Debtors" means any and all claims which Alclin may, from time to time, have against its debtors, whether present or future, including, without limiting the generality of the foregoing, Alclin's book debts;

- (b) “Debtors Report” means a report reflecting:
- (i) the names, addresses and other contact information which Alclin has in relation to each of the debtors which comprise the Debtors;
  - (ii) the nature and amount of the Debtors; and
  - (iii) full particulars of all and any bills of exchange, acknowledgements of debt, cheques, promissory notes, negotiable instruments or the like held by Alclin in respect of the Debtors, if so requested by the Lender in writing prior to delivery of the Debtors Report (it being recorded that the Lender shall be entitled to make such a request in respect of a single Debtors Report, any number of Debtors Reports, or all Debtors Reports until such time as the request is revoked);
- (c) “Encumber” means in relation to any asset, to encumber such asset in any way including but not limited to by way of a pledge, a cession in *securitatem debiti*, a general notarial bond, a special notarial bond, a deed of hypothecation, a mortgage bond, a charge fixed or floating, or to grant any other similar or analogous security interest of any nature whatever over such asset;
- (d) “Evidentiary Documents” means, collectively, the Debtors Report and, from time to time, and the Documents of Title; and

12.2 “Machinery Agreement” means agreement between ESCO and Alclin, irrespective of its form, in terms of which the Alclin is purchasing the Machinery from ESCO.

12.3 Alclin hereby cedes in *securitatem debiti*, to and in favour of the Lender, all of Alclin’s present and future right, title, benefit and interest in, to and under:

- (a) the Debtors; and
- (b) the Machinery Agreement,

collectively, “the **Ceded Rights**”.

- 12.4 Without prejudice to any other provision of this Agreement, if Alclin has pledged, ceded or otherwise Encumbered any of the Ceded Rights to any other party prior to the Signature Date, this Agreement shall (without affecting the operation of this Agreement in respect of those of the Ceded Rights which have not been so ceded to another party) constitute a cession in *securitatem debiti* to the Lender of Alclin's reversionary rights, (including any of Alclin's rights of action against such other party and any rights which may now or in the future vest in Alclin pursuant to such reversionary rights) in respect of those Ceded Rights. The Lender shall be entitled to notify such other party of this Agreement.
- 12.5 This Agreement and the Cession incorporated herein are without prejudice and in addition to, and not in substitution of, any other Security. The validity and/or operation of any other Security shall not be affected by this Agreement.
- 12.6 Within 10 (Ten) Business Days of written demand by the Lender, Alclin shall deliver to the Lender, or procure the delivery to the Lender of, originals of the Evidentiary Documents as at the date of demand, duly endorsed or negotiated (where applicable), together with any relevant correspondence.
- 12.7 If Alclin is in breach of this Agreement (including the occurrence of an Event of Default) then, without prejudice to the Lender's other rights at law or in terms of this Agreement, all amounts owing by Alclin to the Lender, whether in terms hereof or otherwise, shall, at the written election of the Lender, immediately become due and payable and the Lender shall be entitled but not obliged, without notice to Alclin and without first obtaining any order of court:
- (a) either:
- (i) to cause all or any of the Ceded Rights to be sold either by public auction or private treaty, as the Lender in its sole and absolute discretion deems fit; or
  - (ii) without prejudice to the rights of the Lender to purchase such Ceded Rights at any such sale by public auction, to acquire all or any of the Ceded Rights at a price equal to the fair value thereof which, in the absence of agreement, shall be



determined by any auditor appointed for this purpose by the President for the time being of the South African Institute of Chartered Accountants at the request of the Lender. Such auditor shall act as an expert and not as an arbitrator, shall determine such fair value in his sole and absolute discretion and his decision shall, in the absence of a manifest error in calculation, be final and binding on the Parties; and/or

- (b) to convey valid title in the Ceded Rights to any purchaser thereof (including the Lender itself); and/or
- (c) to recover and retain and give a valid receipt for any amount due in terms of or in respect of any of the Ceded Rights directly from the debtors or any other person; and/or
- (d) to grant any indulgence, leniency, extension of time and/or to compromise, release, abandon or waive any right or *spes* which relates to or constitutes part of the Ceded Rights, including any right against Alclin, any right against any surety or guarantor and any right in terms of any other Security.

12.8 The Lender shall apply the net proceeds of any disposal or recovery referred to in clause 12.7 (after deducting therefrom all costs and expenses incurred by the Lender, in its sole and absolute discretion, in connection with such sale, acquisition or recovery and the exercise by the Lender of its rights) in reduction or discharge, as the case may be, of Alclin's indebtedness to the Lender, without prejudice to the Lender's right to recover from Alclin any balance which may remain owing to the Lender after the exercise by the Lender of its rights. The Lender shall pay to Alclin any surplus of such net proceeds remaining after complete discharge of Alclin's indebtedness to the Lender.

12.9 Alclin hereby irrevocably and *in rem suam* nominates, constitutes and appoints such officer or employee of the Lender, as shall from time to time be nominated for this purpose by the Lender, as Alclin's sole and exclusive attorney and agent in Alclin's name, place and stead, to sign and execute all such documents and to do all such things as such officer in his sole and absolute discretion may consider to be necessary or desirable to give effect to this Agreement (including this clause).

12.10 The Parties acknowledge and agree that -

- (a) the obligations of Alclin are obligations of a commercial nature; and
- (b) the application of the provisions of this clause will confer upon the Lender certain procedural benefits which, in light of the commercial nature of the transaction secured by this Agreement, are fair, reasonable and necessary to ensure that the Lender does not suffer unfair commercial prejudice.

12.11 Without prejudice to any other rights and remedies which the Lender may have at law, in terms of this Agreement and shall be severable and divisible from the other terms and conditions of this Agreement if found to be invalid or unenforceable. In this regard the Parties record that the terms hereof would constitute a cession even if the *parate executie* terms included herein were not agreed upon and accordingly, even if the *parate executie* terms are found to be invalid or unenforceable, the remaining provisions of this Agreement are intended to remain of full force and effect.

13. **Stipulatio Alteri**

13.1 For the avoidance of all doubt, to the extent that Tony G-Co in its sole discretion deems it necessary for *inter alia* Canadian regulatory, funding, taxation or other reasons, it shall nominate one or more Tony G-Co Nominee to exercise the lending rights of Tony G-Co, in respect of any Loan Portion.

13.2 To the extent that any provision of this Agreement constitutes a stipulation for the benefit of any Tony G-Co Nominee that is not party hereto, such stipulation shall be deemed to have been accepted by each such Tony G-Co Nominee upon such Tony G-Co Nominee giving notice of such acceptance to the Parties, at which time the Tony G-Co Nominee will become party to this Agreement in respect of the relevant Loan Portion.

14. **Specific Transaction Agreement Provisions**

The Parties shall be bound by:

14.1 the warranties provisions of clause 11;

- 14.2 the indemnity provisions of clause 12;
- 14.3 the confidentiality provisions of clause 13;
- 14.4 the notices and *domicilia* provisions of clause 16;
- 14.5 the mutual support provisions of clause 17;
- 14.6 the dispute resolution provisions of clause 19; and
- 14.7 the general provisions of clause 20,

of the Transaction Agreement, each of which is:

- 1) herein incorporated by reference thereto; and
- 2) amended to the extent necessary so as to apply to this Agreement *mutatis mutandis*.

15. **Counterparts**

This Agreement may be executed in counterparts, each of which when executed and delivered will constitute an original, but all of which together will constitute the same agreement.

Signed at [redacted] on November 16, 2023

For and on behalf of

**TONY G-CO INVESTMENT HOLDINGS LIMITED**

"Ron Akram"

Name: Ron Akram

Capacity: Chief Executive Officer

Who warrants authority

Signed at [redacted] on November 16, 2023

For and on behalf of **ALCLIN MANUFACTURING PROPRIETARY LIMITED**

"Christo Coetzee "

Name: Christo Coetzee

Capacity: Sole director

Who warrants authority

Signed at [redacted] on November 16, 2023

For and on behalf of **ALCLIN PROPRIETARY LIMITED**

"Christo Coetzee "

Name: Christo Coetzee

Capacity: Sole director

*Who warrants authority*

Signed by **Coetzee** at [redacted] on November 16, 2023

"Christo Coetzee "

**CHRISTO GUSTAV COETZEE**